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Background: Lamin A/C (LMNA) mutation carriers suffer from a variety of clinical phenotypes, including dilated
cardiomyopathy (DCM). Although it has been suggested that carriers are at risk for thromboembolic complica-
tions, it is unknownwhether this risk is higher than can be expected from the underlying cardiac abnormalities.
The purpose of this study was to determine whether a LMNA mutation is associated with an increased risk of
thromboembolic complications.
Methods: We compared a cohort of 76 LMNA mutation carriers with a cohort of 224 idiopathic DCM patients
without a LMNAmutation, with respect to the prevalence of arterial and venous thromboembolic complications.
Furthermore, we carried out a case–control study to explore whether a prothrombotic phenotype was present
in LMNAmutation carriers without DCM or atrial tachyarrhythmias (n=14) and compared this with mutation
negative relatives (n=13).
Results: The prevalence of thromboembolic complications was higher in the cohort of LMNA mutation carriers
than in DCM patients (22 vs 11%; pb0.05), after respectively mean follow-up of 42±12 and 49±12 years.
After adjustment for possible confounders, including atrial tachyarrhythmias and left ventricular ejection
fraction, LMNA mutation carriership was independently associated with an increased risk of thromboembolic
complications (HR 4.8, 95% CI: 2.2–10.6). The results of the case–control study suggested a prothrombotic
phenotype in LMNA mutation carriers, as reﬂected by an altered platelet function and increased thrombin
generation.
Conclusions: LMNAmutation is independently associated with an increased risk of arterial and venous thrombo-
embolic complications. Laboratory research in LMNA mutation carriers without severe cardiac abnormalities
suggests a prothrombotic phenotype.© 2012 Elsevier Ireland Ltd. All rights reserved.ioventricular block; CI, conﬁ-
antable cardioverter deﬁbrilla-
t ventricular ejection fraction;
AP, thrombin receptor activat-
ability and freedom from bias of
dicine, AMC, Academic Medical
am, P.O. Box 22660, 1100 DD
: +31 20 6976177.
sma).
Ltd. All rights reserved.1. Introduction
The LMNA gene encodes intermediate ﬁlament proteins lamin A
and lamin C, which are components of the nuclear lamina [1].
Mutations in LMNA are related to more than a dozen different pheno-
types, collectively described as laminopathies [2].
The majority of the pathogenic mutations in LMNA result in cardi-
ac abnormalities, with or without muscular dystrophy [3,4]. The car-
diac phenotype is characterized by conduction disorders, atrial and
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ventricular arrhythmias and DCM are often severe, and result in a
poor prognosis of individuals carrying a LMNA mutation [6,7]. Apart
from the cardiac morbidity an increased risk of thromboembolic
complications has been suggested in anecdotal reports [8,9]. These re-
ports, with a modest number of LMNAmutation carriers, are however
inconclusive since it is unknown whether the observed events are
higher than expected based on the cardiac abnormality (e.g. atrial
ﬁbrillation and/or DCM) per se [10–12].
Therefore, the aim of the present study was to determine whether a
LMNAmutation is associated with an increased risk of thromboembolic
complications, both arterial and venous. We carried out two different
studies to investigate this. First, a cohort of LMNA mutation carriers
was compared with a cohort of idiopathic DCM patients without a
LMNA mutation, to verify whether a LMNA mutation is independently
associated with an increased risk of thromboembolic complications.
Secondly, we explored whether a prothrombotic phenotype was
present in LMNA mutation carriers compared with mutation negative
relatives.
2. Methods
2.1. Study designs
We carried out two different studies, i.e. a cohort and a case–control study.
2.2. Cohort study
The cohort study was a retrospective observational study, comparing a cohort of
LMNA mutation carriers with a cohort of idiopathic DCM patients.
2.2.1. Cohort of LMNA mutation carriers
All consecutive individuals (probands and relatives) diagnosed with a pathogenic
cardiac disease causing LMNA mutation, between January 2000 and December 2010,
from two referral centers (the Academic Medical Center Amsterdam and the University
Medical Center Groningen, The Netherlands), were eligible for the study. The deﬁnition
of pathogenic LMNA mutation has been described previously [13].
2.2.2. Cohort of DCM patients
All consecutive individuals (probands), diagnosed with idiopathic DCM who were
referred in the same period to the outpatient clinics of the clinical genetics depart-
ments of the same centers (and underwent LMNA screening), who did not carry a
LMNA mutation were eligible for this cohort.
We only included individuals who were at least 16 years of age and who had been
investigated by a cardiologist at least once. Clinical information about the cardiac and
muscular phenotype and medical history were collected.
The principal outcome for the analysis was the composite end-point of either an
arterial or venous thromboembolic complication.
Arterial thromboembolic complications were deﬁned as ischemic stroke or tran-
sient ischemic attack diagnosed by a neurologist or acute peripheral arterial occlusion
diagnosed by appropriate imaging.
Venous thromboembolic complications were deﬁned as deep vein thrombosis or
pulmonary embolism diagnosed by appropriate imaging.
2.3. Case–control study
All consecutive LMNA mutation carriers diagnosed with a pathogenic (cardiac dis-
ease causing) LMNA mutation and relatives who tested negative for the familial LMNA
mutation between January 2000 and December 2010 in the Academic Medical Center,
Amsterdam, The Netherlands, were eligible for this study. Individuals diagnosed with
DCM with left ventricular ejection fraction (LVEF) ≤45% and atrial tachyarrhythmias
or receiving vitamin K antagonists were excluded, to rule out their inﬂuence on the
platelet and hemostatic characteristics. Complete medical history (including medica-
tion use), physical examination and blood analysis on platelet and hemostatic charac-
teristics were carried out.
Several exploring platelet and hemostatic characteristics were assessed. Regarding
the platelet characteristics, platelet number, mean platelet volume (MPV) and platelet
function were measured. Flow cytometry (on a Calibur ﬂow cytometer BD Biosciences)
was performed to measure the basal and stimulated platelet activation (P-selectin) and
monocyte–platelet complexes. Platelets were stimulated with arachidonic acid (AA,
BIO/DATA Corporation, Horsham, PA) or thrombin receptor activating peptide (TRAP,
Bachem AG, Bubendorf, Switzerland). Data were analyzed by CellQuest Pro (version
4.02; BD Biosciences).
The hemostatic characteristics were explored by measuring the end products of
the coagulation cascade. We therefore, determined fragment 1+2 (marker for in
vivo thrombin generation) and ex vivo thrombin generation, after stimulation withtissue factor (initiator of the coagulation cascade). Both the platelet and hemostatic
measurements have been described previously [14,15].
The protocol was approved by the institutional review board of the Academic
Medical Center, in Amsterdam, The Netherlands. All subjects provided written informed
consent.
2.4. Risk factors for thromboembolic complications
2.4.1. Cardiac risk factors for thromboembolic complications
Atrial tachyarrhythmias were deﬁned as paroxysmal (episode of atrial ﬁbrillation
for more than 30 s), persistent and permanent atrial ﬁbrillation and atrial ﬂutter. Atrio-
ventricular (AV)-block was deﬁned as a ﬁrst (PR interval ≥0.20 s), second or third de-
gree block. LVEF was determined by echocardiography, and deﬁned as severely
reduced (b35%), moderately reduced (35–55%), or normal (>55%). Cardiac device im-
plantation was deﬁned as both pacemaker and cardioverter deﬁbrillator implantation.
2.4.2. Non-cardiac risk factors for thromboembolic complications
Hypertension was deﬁned as a systolic blood pressure of more than 140 mm Hg or
a diastolic blood pressure of more than 90 mm Hg (or both) on at least two occasions
or the use of antihypertensive medication. Diabetes mellitus was diagnosed based on
the criteria of the American Diabetes Association or the use of antidiabetic drugs
[16]. Body mass index (BMI) was calculated by dividing the weight in kilograms by
the square of the height in meters. Smoking was deﬁned as current (case–control
study) or current and former habitual (cohort study) daily use of 10 or more cigarettes.
Oral contraceptive use was deﬁned by current or former use of oral contraceptive for
more than 1 year, during clinical follow-up by a cardiologist. Individuals were classi-
ﬁed as having muscular dystrophy, when it was diagnosed by a neurologist.
2.5. Statistical analysis
The clinical characteristics in both studies were compared using the Student's
t-test or Mann–Whitney U test for continuous variables (depending on whether the
variable was supposed to be normally distributed) and the chi-square test in case of
categorized variables expressed as proportions.
For the cohort study, we modeled time-to-event, from date of birth until an arterial
or venous thromboembolic complication occurred (before the start of antiplatelet or
anticoagulant therapy). Individuals were censored when antiplatelet or oral anticoagu-
lant therapy was started (for any reason) or most recent evaluation in individuals
without antiplatelet or oral anticoagulant therapy. Multivariate Cox regression analysis
was used to assess the association between carrying a LMNAmutation and arterial and/
or venous thromboembolic complications, independent of confounders for thrombo-
embolic complications. Hazard ratios (HR) and 95% conﬁdence interval (CI) were
calculated; robust standard errors were calculated to account for family-clustering in
the data [17,18]. Adjustments were made for known thromboembolic risk factors, in-
cluding gender, cardiac device implantation, atrial tachyarrhythmias, oral contracep-
tive use, diabetes mellitus, smoking, hypertension, LVEF, AV-block and muscular
dystrophy. Missing data were less than 10% per variable and imputed when necessary.
Imputations were done randomly based on mean or median proportions of the com-
plete group per variable.
For the case–control study, platelet and hemostatic characteristics were compared
between LMNA mutation carriers and their mutation negative relatives, using mixed
model analyses, with LMNA mutation carriers and their relatives as pairs.
The SPSS software version 17.0 (SPSS Inc., Chicago, Illinois) and the R statistical
package (version 2.10.1) were used for analyses [19]. A p-value of b0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Cohort study
3.1.1. Study population and characteristics
The cohort included 76 LMNA mutation carriers from 22 different
families (range 1 to 24 individuals per family) and 224 DCM patients
without a LMNA mutation (Table 1). LMNA mutation carriers were
signiﬁcantly younger than DCM patients (45 vs 51 years, pb0.05).
Furthermore, LMNA mutation carriers had more often muscular
dystrophy (33 vs 1%; pb0.05), atrial tachyarrhythmias (63 vs 21%;
pb0.05), and conduction disorders (67 vs 14%; pb0.05) and a cardiac
device was more often implanted (64 vs 51%; pb0.05) as compared
with DCM patients. In contrast, the prevalence of a LVEF b35% (69
vs 17%; pb0.05) and prevalence of hypertension (19 vs 8%; pb0.05)
were higher in DCM patients compared with LMNA mutation
carriers. Other thromboembolic risk factors were similar between
both groups.
Table 1
Cohort study: characteristics of LMNA mutation carriers compared with DCM patients.
LMNA mutation carriers
(n=76)
DCM patients
(n=224)
Age—years 45±13 51±12⁎
Male 41 (54) 121 (54)
Thromboembolic complications 17 (22) 25 (11)⁎
Venous 6 (8) 9 (4)
Arterial 11 (14) 16 (7)
Dysrhythmias
Atrial tachyarrhythmias 48 (63) 47 (21)⁎
AV-block 51 (67) 32 (14)⁎
LV function
LVEF b35% 13 (17) 154 (69)⁎
LVEF 35–55% 22 (29) 70 (31)
LVEF >55% 41 (54) 0 (0)
Risk factors for thromboembolic
complications
Hypertension 6 (8) 43 (19)⁎
Diabetes mellitus 3 (4) 22 (10)
Smoking 27 (36) 74 (33)
Medication
Oral anticoagulation and/or
antiplatelet therapy
46 (61) 147 (66)
Oral contraceptive 3 (4) 1 (0)
Cardiac device 49 (64) 115 (51)⁎
Muscular dystrophy 25 (33) 2 (1)⁎
Pathogenic mutation
LMNA 76 (100) 0 (0)
PLN 0 (0) 25 (11)a
MYH7 0 (0) 1 (0)
TPM1 0 (0) 1 (0)
TNNT1 0 (0) 1 (0)
SCN5A 0 (0) 1 (0)a
All variables are mentioned as number (%), except for age, which is mentioned as
mean±standard deviation (SD). AV-block = atrioventricular block, DCM = dilated
cardiomyopathy, LV = left ventricular, LVEF = left ventricular ejection fraction,
Smoking = former or current smoker.
⁎ p-Valueb0.05.
a One individual carried mutations in both genes.
Table 2
Cox regression analysis of the cohort study: risk of
thromboembolic complications in LMNA mutation car-
riers compared with DCM patients.
Hazard ratio
(95% CI)
Model 1 3.5 (1.9–6.7)⁎
Model 2 3.6 (1.9–6.9)⁎
Model 3 4.8 (2.2–10.6)⁎
Model 1: crude,Model 2: sex adjusted,Model 3: additionally
adjusted for family-clustering, cardiac device implantation,
atrial tachyarrhythmias, oral contraceptive use, diabetes
mellitus, smoking, hypertension, LVEF, muscular dystrophy
and AV-block. CI = conﬁdence interval.
⁎ p-Valueb0.05.
Fig. 1. Cohort study: event-free survival of LMNA mutation carriers compared with
DCM patients. Survival curve of LMNA mutation carriers compared with idiopathic
DCM patients corrected for confounders: family-clustering, cardiac device implanta-
tion, gender, atrial tachyarrhythmias, oral contraceptive use, diabetes mellitus,
smoking, hypertension, LVEF, muscular dystrophy and AV-block. Follow-up in years
of age, from date of birth until thromboembolic complication. In individuals without
a thromboembolic complication the follow-up period was censored at the start of
oral anticoagulant/antiplatelet therapy or most recent evaluation. CI = conﬁdence in-
terval, DCM = dilated cardiomyopathy, Event = occurrence of thromboembolic com-
plications, HR = hazard ratio.
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The prevalence of thromboembolic complications was signiﬁcant-
ly higher among LMNA mutation carriers compared with DCM pa-
tients (22 vs 11% respectively; pb0.05), after a respectively total
follow-up of 3173 (mean follow-up of 42±12 years) and 10,893
(mean follow-up of 49±12 years) patient-years. In the largest family
consisting of 24 LMNA mutation carriers 5 (21%) thromboembolic
complications occurred, and in the remaining 52 LMNAmutation car-
riers from the other families 12 (23%) thromboembolic complications
occurred. The prevalence of arterial thromboembolic complications
was respectively 14 vs 7% and the prevalence of venous thromboem-
bolic complications was respectively 8 vs 4%. The mean age of onset
of thromboembolic complications was comparable between both
groups, with a mean age of 45±10 years for LMNAmutation carriers
and 47±12 years for DCM patients.
Carrying a LMNA mutation was associated with an increased
risk of thromboembolic complications (HR 3.5, 95% CI: 1.9–6.7)
(Table 2). This association remained present after adjustment for pos-
sible confounders (HR 4.8, 95% CI: 2.2–10.6) (Fig. 1). For the separate
components of thromboembolic events, i.e. arterial and venous, the
hazard ratios were also signiﬁcant, respectively 5.6 (95% CI: 2.3–
14.0) and 6.5 (95% CI: 1.7–25.8).
Since LMNA mutation carriers had a higher prevalence of atrial
tachyarrhythmias, we also analyzed the data stratiﬁed for atrial
tachyarrhythmias. In both strata, with and without atrial tachyar-
rhythmias, the LMNA mutation carriers had an increased risk of
thromboembolic complications, with hazard ratios of respectively
6.0 (95% CI: 2.0–18.1) and 5.3 (95% CI: 1.9–14.8) (Fig. 2).3.2. Case–control study
3.2.1. Study population and characteristics
We included in total 27 individuals from 8 different families. This
rendered us 14 individuals with a LMNA mutation and 13 mutation
negative relatives. Table 3 displays the main characteristics of the
case–control study population as well as the prevalence of risk factors
for thromboembolic complications. In the 14 LMNA mutation carriers
and 13 mutation negative relatives, baseline characteristics and risk
factors for thromboembolic complications were comparable.
3.2.2. Platelet and hemostatic characteristics
Concerning the platelet characteristics (Table 4): LMNA mutation
carriers had a decreased platelet count compared with relatives
(205 vs 248×109/L, respectively; pb0.05). Furthermore, the MPV
tended to be higher in LMNA mutation (11.2 vs 10.4 fL, respectively;
p=0.08). There was no difference with regard to the basal level of
platelet activation, i.e. the platelet activation status in blood without
an inducer. Upon stimulation with TRAP, however, the response of
Fig. 2. Cohort study: event-free survival of LMNA mutation carriers compared with
DCM patients stratiﬁed according to atrial tachyarrhythmias. Survival curve of LMNA
mutation carriers compared with idiopathic DCM patients stratiﬁed according to atrial
tachyarrhythmias and corrected for confounders: family-clustering, cardiac device im-
plantation, gender, oral contraceptive use, diabetes mellitus, smoking, hypertension,
LVEF, muscular dystrophy and AV-block. Follow-up in years of age, from date of birth
until thromboembolic complication. In individuals without a thromboembolic compli-
cation the follow-up period was censored at the start of oral anticoagulant/antiplatelet
therapy or most recent evaluation. CI = conﬁdence interval, DCM= dilated cardiomy-
opathy, Event = occurrence of thromboembolic complications, HR = hazard ratio.
Table 3
Case–control study: characteristics of LMNAmutation carriers compared with mutation
negative relatives.
LMNA mutation carriers
(n=14)
Relatives
(n=13)
Age—years 41 (32–56) 39 (24–53)
Male 7 (50) 9 (69)
Thromboembolic complication 2 (14) 1 (8)
Arterial 1 (7) 1 (8)
Venous 1 (7) 0 (0)
LVEF
45–55% 4 (29) –
>55% 10 (71) –
Risk factors for thromboembolic
complications
Hypertension 2 (14) 1 (8)
Diabetes mellitus 1 (7) 0 (0)
Current smoker 4 (29) 3 (23)
Body mass index—kg/m2 26 (21–28) 25 (24–27)
Medication
Antiplatelet therapy 1 (7) 1 (8)
Oral contraceptive 2 (14) 1 (8)
All variables are mentioned as number (%), except for age and BMI, which is mentioned
as median (IQR). BMI = body mass index, IQR = interquartile range, LVEF = left ven-
tricular ejection fraction. – Data not available. all p-values are>0.05.
Table 4
Case–control study: platelet and hemostatic characteristics of LMNA mutation carriers
compared with mutation negative relatives.
LMNA mutation carriers
(n=14)
Relatives
(n=13)
Platelets
Platelets—109/L 205±35 248±54⁎
MPV—fL 11.2±1.0 10.4±1.0
Platelets activation—% P-selectin
No inducer 4.7±2.3 5.0±3.0
AA 0.5 mM 59±19 69±13
TRAP 15 μM 83±24 94±4⁎
Monocyte–platelet complexes—no.
of events
No inducer 12±11 9±7
AA 0.5 mM 60±33 98±57⁎
TRAP 15 μM 155±73 176±55
Thrombin generation test
Prothrombin fragment 1+2—pM 166±79 156±69
Peak—nM 312±35 273±58⁎
Time to peak—min 6.0±0.8 6.5±1.2
Velocity index—nM/min 118±28 91±40⁎
All variables are mentioned as mean±standard deviation (SD).
AA = arachidonic acid, MPV = mean platelet volume, TRAP = thrombin receptor ac-
tivating peptide.
⁎ p-Valueb0.05.
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vs 94% P-selectin; pb0.05). Furthermore, the baseline number of
monocyte–platelet complexes was not statistically different between
LMNA mutation carriers and the relatives (12 vs 9 events; p=0.41).
However, after stimulation the number of platelet–monocyte com-
plexes in LMNA mutation carriers was signiﬁcantly lower. The
number of monocyte–platelet complexes after stimulation with AA
was signiﬁcantly lower in LMNA mutation carriers (60 vs 98 events,
pb0.05).
Concerning the coagulation measurements (Table 4): The throm-
bin generation was signiﬁcantly higher in LMNA mutation carriers,
with a higher peak level (312 vs 273 nM, pb0.05) and higher velocity
index (118 vs 91 nM/min, pb0.05). On the other hand, the prothrom-
bin fragment 1+2 concentration, was comparable in both groups.4. Discussion
The present study demonstrates that a LMNAmutation is associat-
ed with an increased risk of thromboembolic complications both arte-
rial and venous. After adjustment for potential confounders including
atrial tachyarrhythmias, the hazard ratio was approximately 5, with
comparable ratios for the components of the thrombotic outcome
separately.
4.1. Independent association between LMNA mutation and
thromboembolic complications
DCM per se is associated with a high risk for thromboembolic
complications due to left ventricular dilatation, decreased LVEF and
atrial tachyarrhythmias [10,11,20]. However, the results from our
study showed that the prevalence of both arterial and venous throm-
boembolic complications in LMNA mutation carriers was even higher
than in idiopathic DCM patients. Noteworthy, the cohort of LMNA
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ing presymptomatic mutation carriers. We thus conﬁrmed the earlier
anecdotic reports by van Tintelen et al. and Boriani et al., both
reporting a high prevalence of thromboembolic complications in
LMNAmutation carriers [8,9]. Interestingly, carrying a LMNAmutation
was associated with an increased risk for thromboembolic complica-
tions, independent of thromboembolic risk factors such as atrial
tachyarrhythmias, LVEF and cardiac device implantation.
One might argue, whether this observed increased risk might not
be due to unrecognized paroxysmal atrial tachyarrhythmias. Indeed
some individuals could have had unidentiﬁed atrial tachyarrhyth-
mias. Since this will also be the case for the DCM individuals, we be-
lieve this has only limited inﬂuence. To further conﬁrm this, the
analysis stratiﬁed for individuals with or without known atrial tachy-
arrhythmias did not materially change the results. In the stratum of
individuals with atrial tachyarrhythmias the risk of thromboembolic
complications was still higher than in those individuals carrying a
LMNA mutation.
4.2. Prothrombotic phenotype
After further blood analysis in LMNAmutation carriers without DCM
or atrial tachyarrhythmias, we identiﬁed a prothrombotic phenotype.
These LMNA mutation carriers had, compared with mutation negative
relatives, differences in both platelet and hemostatic characteristics.
We found that LMNAmutation carriers had a signiﬁcantly reduced
platelet number and that both platelets and platelet–monocyte com-
plexes were less sensitive to stimulation in vitro with an agonist. Fur-
thermore, the platelets of these LMNA mutation carriers tended to
have an increased MPV, which itself is an independent predictor of is-
chemic stroke and cardiovascular disease because larger platelets are
metabolically and enzymatically more active and are prothrombotic
[21,22]. This may reﬂect mild ongoing platelet activation in vivo
[23] since activated platelets in vivo will lose their P-selectin, either
by losing P-selectin on the surface or by binding to surface-exposed
P-selectin monocytes [24,25]. Because of the in vivo activation, the
expression of P-selectin after stimulation with an agonist will be re-
duced in vitro.
Concerning the hemostatic characteristics, a similar phenomenon
was observed. The coagulation system (prothrombin fragment 1+2)
was not activated at baseline. The hemostatic characteristics became
more apparent after stimulation. LMNA mutation carriers produced
more thrombin, which is consistent with the observed clinical pheno-
type with a high prevalence of thromboembolic complications [26,27].
When combining the results of the platelet and hemostatic char-
acteristics, it suggests that the blood of LMNA mutation carriers be-
comes more thrombotic after in vivo stimulation.
4.3. Relation between LMNA mutation and thromboembolic complications
Lamins A and C are major components of the nuclear lamina. The
functions of lamins A and C are not completely understood. It is
known that they are important in maintaining the nuclear architec-
ture, DNA replication and cell cycle regulation [1,28]. One possible ex-
planation for the observed prothrombotic phenotype might be the
direct inﬂuence of the altered lamin A/C protein on the platelets. In
fact, instability of the actin structures, as a result of a LMNAmutation,
could inﬂuence fragmentation of platelets from megakaryocytes
resulting in an altered platelet production/function or could inﬂuence
the function of the platelets themselves [29–32]. On the other hand,
one might speculate that the prothrombotic phenotype is a result of
the inﬂuence of the altered lamin A/C protein in the endothelial
and/or smooth muscle cells of the vessel wall, hereby inﬂuencing
the function of the platelets. It might be of additional value to analyze
whether there is a relation between the location or type of mutationin LMNA and the prothrombotic phenotype, however the number of
LMNA mutation carriers is too modest in this study.
4.4. Study limitations
The ﬁrst part of the study was based on the data of two retrospec-
tively collected cohorts, which are sensitive for biases due to the ab-
sence of diagnostic and treatment protocols. Therefore, patients might
have been treated differently; including different criteria might have
been used to start anticoagulant or antiplatelet therapy. We tried to
avoid this bias by analyzing only the time-period in which the individ-
uals did not receive anticoagulant and/or antiplatelet therapy.
Concerning the case–control study,we selected a young cohort of in-
dividuals without cardiac disease yet and without anticoagulant and/or
antiplatelet therapy. We are aware that the exclusion of these individ-
uals could also have given an underestimation of the effect of the
LMNAmutation on the platelet and hemostatic characteristics.
5. Conclusion
Our results show that carrying a LMNAmutation is independently
associated with an increased risk of both arterial and venous throm-
boembolic complications and opens important new avenues for a
possible role of anticoagulant and/or antiplatelet therapy as appropri-
ate preventive intervention. In our view, physicians who are treating
LMNA mutation carriers need to be aware of the prothrombotic phe-
notype of these individuals.
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